Back to Case Studies
Healthcare / Pharmaceuticals
Pharmaceutical Business Unit Divestiture
January 11, 2025
$425M enterprise value achieved
Transaction Value
Closed transaction in 7 months
Process Timeline
6 qualified bidders participated in auction
Multiple Bidders
Came in 15% under budget
Separation Costs
Disclaimer: This case study was generated with AI assistance for the Frilly Smart Chat demonstration. While based on realistic business scenarios and common consulting outcomes, it represents a fictional engagement. Consult qualified financial professionals for real-world strategic advice.
The Challenge
A large pharmaceutical company decided to divest a non-core business unit to focus on their primary therapeutic areas. The business unit had complex interdependencies with corporate functions, shared manufacturing facilities, and long-term supply agreements that needed to be untangled.
Our Solution
Our team led the financial separation and sell-side due diligence process. We created standalone financial statements, identified and valued stranded costs, developed transition service agreements, and supported management presentations to potential buyers. We worked closely with legal, tax, and HR teams to ensure all aspects of the separation were addressed.
"The complexity of separating this business unit was significant. Synergetic Ecosystems brought order to the process and helped us achieve a valuation that exceeded our expectations. Their attention to detail in the diligence process gave buyers confidence."
— Patricia Williams, VP Corporate Development
Services Provided
Mergers Acquisitions Risk Assessment